Research & Development
Carcinoma: Page 2
Bayer, Tempus join forces on cancer testing
The assay will be available for a subset of patients with metastatic colorectal cancer (mCRC), as well as those with radioactive iodine refractory differentiated metastatic thyroid carcinoma (RAIR thyroid cancers).
December 10, 2020
Prelude highlights ASTRO data on breast cancer risk test
The study included nearly 1,800 women diagnosed with ductal carcinoma in situ (DCIS) and classified as low risk by radiation oncology/toxicity grading-like criteria for recurrence of DCIS or progression to invasive breast cancer. The DCISionRT assay reclassified almost half of these patients to elevated risk, which suggests numerous patients would have been undertreated with surgery alone.
October 29, 2020
Fujifilm Medical to add IVD to portfolio
Fujifilm Wako Diagnostics has developed biomarkers that assess the risk of hepatocellular carcinoma in patients with chronic liver disease, as well as IVD reagents for disorders of lipid metabolism, lupus, rheumatoid arthritis, coronary heart disease, and diabetes, according to Fujifilm Medical Systems.
August 16, 2020
Liver cancer diagnostic test offers promise of early detection
The platform is called EV Click Chips, and the hope is that it will enable more effective purification of extracellular vesicles in blood from people with hepatocellular carcinoma. Researchers from the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center have received a $2.97 million grant from the U.S. National Cancer Institute (NCI) to develop the technology further.
August 4, 2020
Supplementing imaging with urine test boosts detection of adrenal cancer
The researchers proposed a "triple test strategy" that combines a urine test, computed tomography (CT), and characterization of the tumor size (specifically, whether the maximum tumor diameter was less than 4 cm or greater than or equal to 4 cm). This trifecta of criteria had the highest specificity and sensitivity of any of the tested methods.
July 27, 2020
Molecular genotyping shines light on serous ovarian cancer
High-grade serous ovarian cancer is the most malignant form of ovarian cancer, causing up to 70% of ovarian cancer deaths. The new study validated a new classifier tool called the predictor of high-grade serous ovarian carcinoma (HGSOC) molecular subtype (ProType), which encompasses 55 genes plus five housekeeping genes and is based on the NanoString platform.
June 17, 2020
Google reports pathology AI helps predict survival in cancer patients
The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.
June 17, 2020
Blood test identifies patients at risk for liver cancer
The test analyzes patients' previous viral exposure to accurately predict whether they might develop hepatocellular carcinoma (HCC). It was created by researchers from the U.S. National Institutes of Health and several academic centers to help improve liver cancer screening and early detection.
June 11, 2020
Study calls for hepatitis D screening in at-risk patients
A review of the literature suggests that those who have hepatitis D along with hepatitis B have up to three times the risk for developing hepatocellular carcinoma than if they had hepatitis B alone, reported researchers at the University of Geneva and Geneva University Hospitals, in an article in press. This assessment was based on an analysis of data from 93 studies including a total of more than 100,000 patients.
May 19, 2020
FDA approves Agilent assay for lung cancer
The test, called PD-L1 IHC 28-8 pharmDx, will help physicians identify patients with metastatic NSCLC who qualify for treatment with a dual immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both of which are manufactured by Bristol Myers Squibb.
May 17, 2020
Bayer, NeoGenomics offer free genomic testing for thyroid, colorectal cancers
Under the program, genomic cancer testing for NTRK gene fusions will be available at no cost for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). More commonly found in these patients, NTRK fusions have been shown to drive tumor growth and may play a role in disease management, according to the companies.
May 5, 2020
Study urges broader genetic testing of breast cancer patients
The National Comprehensive Cancer Network's (NCCN) current guidelines for genetic testing recommend it for women younger than 46 who are diagnosed with breast cancer, regardless of family history or cancer subtype. But expanding the age range for genetic testing would help identify more women with mutations that make them vulnerable, concluded first author Dr. Siddhartha Yadav, a hematology-oncology fellow at the Mayo Clinic in Rochester, MN, and colleagues.
March 3, 2020
Page 2 of 3